北米の軽度認知障害（MCI）治療市場、疾患タイプ別（健忘性MCI、非健忘性MCI）、治療タイプ別（投薬、療法）、投与経路別（経口、非経口、その他）、薬剤タイプ別（ブランド、ジェネリック）、性別タイプ別（男性、女性）、年齢タイプ別（小児、成人、高齢者）、エンドユーザー別（病院、専門クリニック、在宅ケア、その他）、流通チャネル別（病院薬局、小売薬局）、国別（米国、カナダ、メキシコ）– 2029年までの業界動向と予測
市場分析と洞察：北米の軽度認知障害（MCI）治療市場
軽度認知障害（MCI）治療市場は、2022年から2029年の予測期間に市場が成長すると予想されています。データブリッジマーケットリサーチは、市場は2022年から2029年の予測期間に9.0％のCAGRで成長し、2029年までに62,355.90千米ドルに達すると分析しています。主要企業が提供する幅広いポートフォリオと、軽度認知障害に対する意識の高まりが、市場成長の原動力となることが期待されています。
軽度認知障害 (MCI) は、日常生活のほとんどの活動を自力でこなす能力を維持している個人における、記憶喪失またはその他の認知能力 (言語または視覚/空間認識など) 喪失の初期段階です。MCI はさまざまな理由で発症する可能性があり、MCI を患っている個人は認知症を発症する可能性があります。MCI は、アルツハイマー病などの神経変性疾患の疾患連続体の初期段階である可能性があります。個人によっては、MCI が正常な認知に戻るか、安定したままになります。
軽度認知障害 (MCI) は、単一の認知領域 (通常は記憶) の障害 (健忘性 MCI)、または複数の認知領域における中程度の障害を特徴とします。長期ケア施設で生活する人の MCI 有病率は、多くの介護施設では 5% ～ 10% ですが、最大 30% にまで及びます。最も頻繁に見られる MCI の形態は健忘性型です。MCI のあまり一般的でない変異体では、前頭側頭葉変性症 (FTLD) における実行機能障害など、他の認知領域の局所的な障害が見られます。
軽度認知障害（MCI）治療市場の世界的成長を牽引する主な要因は、高齢患者数の増加であり、完璧で効果的な治療法を見つけるための継続的な研究が、今後の市場の成長を牽引すると予想されています。ただし、治療手順の高コストと製品関連の有害リスクが市場の成長を妨げる可能性があります。
軽度認知障害 (MCI) 治療市場レポートでは、市場シェア、新開発、製品パイプライン分析、国内および現地の市場プレーヤーの影響の詳細、新たな収益源、市場規制の変更、製品承認、戦略的決定、製品発売、地理的拡大、市場における技術革新の観点から見た機会の分析が提供されます。分析と軽度認知障害 (MCI) 治療市場のシナリオを理解するには、アナリスト概要について Data Bridge Market Research にお問い合わせください。当社のチームが、収益に影響を与えるソリューションを作成し、希望する目標を達成できるようお手伝いします。
軽度認知障害（MCI）治療市場の範囲と市場規模
軽度認知障害 (MCI) 治療市場は、疾患の種類、治療の種類、投与経路、薬剤の種類、性別、年齢、流通チャネル、およびエンドユーザーに基づいてセグメント化されています。セグメント間の成長は、成長のニッチな領域と市場にアプローチするための戦略を分析し、コアアプリケーション領域とターゲット市場の違いを決定するのに役立ちます。
- 軽度認知障害（MCI）治療市場は、疾患の種類に基づいて、健忘性MCIと非健忘性MCIに分類されます。2022年には、世界中の高齢者人口の増加により、健忘性MCIセグメントが世界の軽度認知障害（MCI）治療市場を支配すると予想されています。
- 治療の種類に基づいて、軽度認知障害（MCI）治療市場は、薬物療法と療法に分類されます。2022年には、MCIの症状に対する即時かつ効果的な影響により、薬物療法セグメントが世界の軽度認知障害（MCI）治療市場を支配すると予想されます。
- 投与経路に基づいて、軽度認知障害（MCI）治療市場は、経口、非経口、その他に分類されます。2022年には、非侵襲性、患者のコンプライアンスの高さ、取り扱いの利便性、特定の滅菌条件を必要としないことから、経口セグメントが世界の軽度認知障害（MCI）治療市場を支配すると予想されています。
- 軽度認知障害（MCI）治療市場は、薬剤の種類に基づいて、ブランド薬とジェネリック薬に分類されます。2022年には、ジェネリック薬セグメントが、ブランド薬に比べて費用対効果が高いため、世界の軽度認知障害（MCI）治療市場を支配すると予想されています。
- 性別に基づいて、軽度認知障害（MCI）治療市場は男性と女性に分けられます。2022年には、男性人口に見られる精神衛生上の合併症の急増により、男性セグメントが世界の軽度認知障害（MCI）治療市場を支配すると予想されています。
- 年齢に基づいて、軽度認知障害（MCI）治療市場は、小児、成人、高齢者に分類されます。2022年には、アジア地域で最も高い増加率を示す脆弱な高齢者人口の急増により、高齢者セグメントが世界の軽度認知障害（MCI）治療市場を支配すると予想されています。
- エンドユーザーに基づいて、軽度認知障害（MCI）治療市場は、病院、専門クリニック、在宅ケア、その他に分類されます。2022年には、入院中のより良く効果的な治療に関する意識の高まりにより、病院セグメントが世界の軽度認知障害（MCI）治療市場を支配すると予想されます。
- 流通チャネルに基づいて、軽度認知障害（MCI）治療市場は、病院薬局、小売薬局に分類されます。2022年には、認定処方者や医療専門家との抗精神病薬の使用と支払い保証の増加により、病院薬局セグメントが世界の軽度認知障害（MCI）治療市場を支配すると予想されます。
軽度認知障害（MCI）治療市場の国別分析
軽度認知障害 (MCI) 治療市場が分析され、市場規模の情報が、上記の国、疾患の種類、治療の種類、投与経路、薬剤の種類、性別、年齢、流通チャネル、およびエンドユーザー別に提供されます。
軽度認知障害（MCI）治療市場レポートの対象国は、米国、カナダ、メキシコです。
完璧で効果的な治療法を見つけるための研究が進行中であるため、米国は軽度認知障害（MCI）治療市場を独占すると予想されています。
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、国別データの予測分析を提供する際には、グローバル ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面する課題、販売チャネルの影響も考慮されます。
軽度認知障害（MCI）治療に対する認識を高めるために主要な市場プレーヤーが戦略的な活動を拡大していることが、軽度認知障害（MCI）治療市場の成長を後押ししています。
軽度認知障害 (MCI) 治療市場では、特定の市場における各国の成長に関する詳細な市場分析も提供されます。さらに、市場プレーヤーの戦略と地理的なプレゼンスに関する詳細情報も提供されます。データは、2011 年から 2020 年までの履歴期間について入手できます。
競争環境と軽度認知障害（MCI）治療市場シェア分析
軽度認知障害 (MCI) 治療市場の競争状況では、競合他社ごとに詳細が提供されます。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と広さ、アプリケーションの優位性、技術ライフライン曲線が含まれます。提供されている上記のデータ ポイントは、軽度認知障害 (MCI) 治療市場に関連する会社の焦点にのみ関連しています。
軽度認知障害（MCI）治療市場で活動している主要企業としては、ファイザー社、F. ホフマン・ラ・ロシュ社、ノバルティス社、アコード UK 社、ドクター・レディーズ・ラボラトリーズ社、ヒクマ・ファーマシューティカルズ社、ビアトリス社、エーザイ株式会社、サン・ファーマシューティカルズ社、ジョンソン・エンド・ジョンソン・サービス社、テバ・ファーマシューティカル・インダストリーズ社、マリンクロット社、アストラゼネカ社、シプラ社、武田薬品工業株式会社、アラガン・エステティクス社、ルピン社、ジュビラント・ファーマモバ社、ラネット社、オーロビンド・ファーマ社、UCB SA、ベルギー、WOCKHARDT などが挙げられます。
例えば、
- 2021年7月、FDAは迅速承認制度を利用してアルツハイマー病患者の治療薬としてバイオジェン・アデュヘルム（アデュカヌマブ）を承認した。
市場プレーヤーによるコラボレーション、製品の発売、事業拡大、賞や表彰、合弁事業、その他の戦略は、軽度認知障害（MCI）治療市場における企業の足跡を強化し、組織の利益成長にも利益をもたらします。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USERS COVERAGE GRID
2.8 DISEASES TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTLE
4.2 PORTERS
5 EPIDEMIOLOGY
6 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: REGULATORY SCENARIO
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN VULNERABLE GERIATRIC POPULATION
7.1.2 INCREASE IN AIR POLLUTION IMPACTS COGNITIVE PERFORMANCE
7.1.3 INCREASING NATIONAL AND INTERNATIONAL INVESTMENTS IN RESEARCH AND DEVELOPMENT OF COGNITIVE DISORDERS TREATMENT
7.1.4 RISE IN INCIDENCE OF NON-COMMUNICABLE DISEASES DUE TO PHYSICAL INACTIVITY
7.2 RESTRAINTS
7.2.1 UNAVAILABILITY OF ANY SPECIFIC TREATMENT
7.2.2 SERIOUS ADVERSE RISK ASSOCIATED WITH MCI TREATMENT DRUGS
7.2.3 HIGH COST OF TREATMENT AND CARE MANAGEMENT IN MCI PATIENTS
7.3 OPPORTUNITIES
7.3.1 PROMOTING PATIENT MENTAL HEALTH PROGRAMS
7.3.2 INNOVATION IN ALTERNATIVE MILD COGNITIVE IMPAIRMENT TREATMENT
7.4 CHALLENGES
7.4.1 LONG PROCESS OF APPROVAL BY REGULATORY BODIES
7.4.2 LACK OF SKILLED PROFESSIONALS
8 COVID-19 IMPACT ON MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET
8.1 PRICE IMPACT
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY
8.4 STRATEGIC DECISIONS BY MANUFACTURERS
8.5 CONCLUSION
9 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE
9.1 OVERVIEW
9.2 AMNESTIC MCI
9.3 NON-AMNESTIC MCI
10 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 MEDICATION
10.2.1 CHOLINESTERASE INHIBITORS
10.2.1.1 DONEPEZIL
10.2.1.2 RIVASTIGMINE
10.2.1.3 OTHERS
10.2.2 BENZODIAZEPINES
10.2.2.1 DIAZEPAM
10.2.2.2 CLONAZEPAM
10.2.2.3 LORAZEPAM
10.2.2.4 TEMAZEPAM
10.2.2.5 ALPRAZOLAM
10.2.2.6 FLUNITRAZEPAM
10.2.2.7 FLURAZEPAM
10.2.2.8 ZOPICLONE
10.2.2.9 OTHERS
10.2.3 GLUTAMATE INHIBITORS
10.2.3.1 RILUZOLE
10.2.3.2 OTHERS
10.2.4 ANTIHISTAMINES
10.2.4.1 CETIRIZINE
10.2.4.2 BROMPHENIRAMINE
10.2.4.3 CHLORPHENIRAMINE
10.2.4.4 CLEMASTINE
10.2.4.5 DIPHENHYDRAMINE
10.2.4.6 FEXOFENADINE
10.2.4.7 LORATADINE
10.2.4.8 OTHERS
10.2.5 MAO INHIBITORS
10.2.5.1 ISOCARBOXAZID
10.2.5.2 PHENELZINE
10.2.5.3 SELEGILINE
10.2.5.4 TRANYLCYPROMINE
10.2.5.5 OTHERS
10.2.6 PROTON PUMP INHIBITORS
10.2.6.1 ESOMEPRAZOLE
10.2.6.2 LANSOPRAZOLE
10.2.6.3 OMEPRAZOLE
10.2.6.4 RABEPRAZOLE
10.2.6.5 PANTOPRAZOLE
10.2.6.6 OTHERS
10.2.7 ALTERNATE THERAPY
10.2.7.1 VITAMIN E
10.2.7.2 GINKO
10.2.7.3 OTHERS
10.2.7.4 OTHERS
10.3 THERAPY
10.3.1 COGNITIVE STIMULATION THERAPY
10.3.2 COGNITIVE BEHAVIORAL THERAPY (CBT)
11 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.2.1 TABLET
11.2.2 SYRUP
11.2.3 OTHERS
11.3 PARENTERAL
11.3.1 INTRAVENOUS
11.3.2 INTRAMUSCULAR
11.3.3 OTHERS
11.4 OTHERS
12 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 GENERICS
12.3 BRANDED
13 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER
13.1 OVERVIEW
13.2 MALE
13.3 FEMALE
14 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE
14.1 OVERVIEW
14.2 GERIATRIC
14.3 ADULT
14.4 CHILD
15 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECIALTY CLINICS
15.4 HOMECARE
15.5 OTHERS
16 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 HOSPITAL PHARMACY
16.3 RETAIL PHARMACY
16.3.1 RETAIL SHOPS
16.3.2 ONLINE PHARMACY
17 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION
17.1 NORTH AMERICA
17.1.1 U.S.
17.1.2 CANADA
17.1.3 MEXICO
18 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 EISAI CO., LTD
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.1.5.1 PRODUCT LAUNCH
20.2 TEVA PHARMACEUTICAL INDUSTRIES LTD
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENT
20.3 NOVARTIS AG
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENT
20.4 VIATRIS, INC
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENT
20.5 SUN PHARMACEUTICALS INDUSTRIES LTD
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENT
20.6 PFIZER INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 REVENUE ANALYSIS
20.6.3 PRODUCT PORTFOLIO
20.6.4 RECENT DEVELOPMENT
20.7 ASTRAZENECA
20.7.1 COMPANY SNAPSHOT
20.7.2 REVENUE ANALYSIS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENT
20.7.4.1 ACQUISITION
20.8 DR. REDDY’S LABORATORIES LTD.
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENTS
20.9 AUROBINDO PHARMA
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORFOLIO
20.9.4 RECENT DEVELOPMENT
20.9.4.1 PRODUCT APPROVAL
20.1 F.HOFFMANN-LA ROCHE LTD.
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE ANALYSIS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENT
20.11 ABBVIE INC.
20.11.1 COMPANY SNAPSHOT
20.11.2 REVENUE ANALYSIS
20.11.3 PRODUCT PORTFOLIO
20.11.4 RECENT DEVELOPMENT
20.11.4.1 DATA PRESENTATION
20.12 ACCORD-UK LTD
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENT
20.13 CIPLA INC.
20.13.1 COMPANY SNAPSHOT
20.13.2 REVENUE ANALYSIS
20.13.3 PRODUCT PORTFOLIO
20.13.4 RECENT DEVELOPMENT
20.14 HIKMA PHARMACEUTICALS PLC
20.14.1 COMPANY SNAPSHOT
20.14.2 REVENUE ANALYSIS
20.14.3 PRODUCT PORTFOLIO
20.14.4 RECENT DEVELOPMENTS
20.15 JOHNSON & JOHNSON SERVICES, INC.
20.15.1 COMPANY SNAPSHOT
20.15.2 REVENUE ANALYSIS
20.15.3 PRODUCT PORTFOLIO
20.15.4 RECENT DEVELOPMENT
20.16 JUBILANT PHARMA LIMITED
20.16.1 COMPANY SNAPSHOT
20.16.2 REVENUE ANALYSIS
20.16.3 PRODUCT PORTFOLIO
20.16.4 RECENT DEVELOPMENT
20.17 LANNETT
20.17.1 COMPANY SNAPSHOT
20.17.2 REVENUE ANALYSIS
20.17.3 PRODUCT PORTFOLIO
20.17.4 RECENT DEVELOPMENT
20.18 LUPIN
20.18.1 COMPANY SNAPSHOT
20.18.2 REVENUE ANALYSIS
20.18.3 PRODUCT PORTFOLIO
20.18.4 RECENT DEVELOPMENT
20.18.4.1 AGREEMENT
20.19 MALLINCKRODT PHARMACEUTICALS
20.19.1 COMPANY SNAPSHOT
20.19.2 REVENUE ANALYSIS
20.19.3 PRODUCT PORTFOLIO
20.19.4 RECENT DEVELOPMENT
20.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
20.20.1 COMPANY SNAPSHOT
20.20.2 REVENUE ANALYSIS
20.20.3 PRODUCT PORTFOLIO
20.20.4 RECENT DEVELOPMENT
20.21 UCB S.A., BELGIUM
20.21.1 COMPANY SNAPSHOT
20.21.2 REVENUE ANALYSIS
20.21.3 PRODUCT PORTFOLIO
20.21.4 RECENT DEVELOPMENT
20.22 WOCKHARDT
20.22.1 COMPANY SNAPSHOT
20.22.2 REVENUE ANALYSIS
20.22.3 PRODUCT PORTFOLIO
20.22.4 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
表のリスト
TABLE 1 COMMON BENZODIAZEPINES AVAILABLE IN THE U.S.-
TABLE 2 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
TABLE 3 NORTH AMERICA AMNESTIC MCI IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 4 NORTH AMERICA NON-AMNESTIC MCI IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 5 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 6 NORTH AMERICA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 7 NORTH AMERICA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 8 NORTH AMERICA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 9 NORTH AMERICA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 10 NORTH AMERICA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 11 NORTH AMERICA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 12 NORTH AMERICA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 13 NORTH AMERICA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 14 NORTH AMERICA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 15 NORTH AMERICA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 16 NORTH AMERICA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 17 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 18 NORTH AMERICA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 19 NORTH AMERICA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 20 NORTH AMERICA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 21 NORTH AMERICA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 22 NORTH AMERICA OTHERS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 23 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 24 NORTH AMERICA GENERICS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 25 NORTH AMERICA BRANDED IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 26 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)
TABLE 27 NORTH AMERICA MALE IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 28 NORTH AMERICA FEMALE IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 29 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 30 NORTH AMERICA GERIATRIC IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 31 NORTH AMERICA ADULT IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 32 NORTH AMERICA CHILD IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 33 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 34 NORTH AMERICA HOSPITALS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 35 NORTH AMERICA SPECIALITY CLINICS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 36 NORTH AMERICA HOMECARE IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 37 NORTH AMERICA OTHERS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 38 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 39 NORTH AMERICA HOSPITAL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 40 NORTH AMERICA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 41 NORTH AMERICA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 42 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)
TABLE 43 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
TABLE 44 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 45 NORTH AMERICA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 46 NORTH AMERICA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 47 NORTH AMERICA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 48 NORTH AMERICA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 49 NORTH AMERICA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 50 NORTH AMERICA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 51 NORTH AMERICA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 52 NORTH AMERICA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 53 NORTH AMERICA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 54 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 55 NORTH AMERICA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 56 NORTH AMERICA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 57 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 58 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)
TABLE 59 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 60 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 61 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 62 NORTH AMERICA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 63 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
TABLE 64 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 65 U.S. MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 66 U.S. CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 67 U.S. BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 68 U.S. GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 69 U.S. MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 70 U.S. PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 71 U.S. ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 72 U.S. ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 73 U.S. THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 74 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 75 U.S. ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 76 U.S. PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 77 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 78 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)
TABLE 79 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 80 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 81 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 82 U.S. RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 83 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
TABLE 84 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 85 CANADA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 86 CANADA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 87 CANADA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 88 CANADA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 89 CANADA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 90 CANADA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 91 CANADA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 92 CANADA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 93 CANADA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 94 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 95 CANADA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 96 CANADA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 97 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 98 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)
TABLE 99 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 100 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 101 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 102 CANADA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 103 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
TABLE 104 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 105 MEXICO MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 106 MEXICO CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 107 MEXICO BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 108 MEXICO GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 109 MEXICO MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 110 MEXICO PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 111 MEXICO ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 112 MEXICO ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 113 MEXICO THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 114 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 115 MEXICO ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 116 MEXICO PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 117 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 118 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)
TABLE 119 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 120 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 121 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 122 MEXICO RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
図表一覧
FIGURE 1 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: END USERS COVERAGE GRID
FIGURE 8 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE AND ASIA-PACIFIC IS ESTIMATED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 ONGOING RESEARCH TO INCREASE THE THERAPEUTICS APPLICATION IS EXPECTED TO DRIVE THE NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 AMNESTIC MCI SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET IN 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET
FIGURE 15 DISEASE BURDEN BY RISK FACTOR, WORLDWIDE, 2019
FIGURE 16 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, 2021
FIGURE 17 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
FIGURE 18 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, CAGR (2022-2029)
FIGURE 19 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 20 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, 2021
FIGURE 21 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, 2020-2029 (USD THOUSAND)
FIGURE 22 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, CAGR (2022-2029)
FIGURE 23 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 24 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 25 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
FIGURE 26 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 27 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 28 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, 2021
FIGURE 29 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, 2020-2029 (USD THOUSAND)
FIGURE 30 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, CAGR (2022-2029)
FIGURE 31 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 32 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, 2021
FIGURE 33 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, 2020-2029 (USD THOUSAND)
FIGURE 34 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, CAGR (2022-2029)
FIGURE 35 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 36 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, 2021
FIGURE 37 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, 2020-2029 (USD THOUSAND)
FIGURE 38 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, CAGR (2022-2029)
FIGURE 39 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, LIFELINE CURVE
FIGURE 40 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, 2021
FIGURE 41 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, 2020-2029 (USD THOUSAND)
FIGURE 42 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, CAGR (2022-2029)
FIGURE 43 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 44 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 45 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
FIGURE 46 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 47 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 48 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: SNAPSHOT (2021)
FIGURE 49 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY COUNTRY (2021)
FIGURE 50 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY COUNTRY (2022 & 2029)
FIGURE 51 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY COUNTRY (2021 & 2029)
FIGURE 52 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 53 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: COMPANY SHARE 2021 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
